Rein Therapeutics Inc Share Price

NASDAQ: RNTX

Small Cap

$1.16

+0.01

(+0.87%)

Live

as on September 18, 2025 at 7:37 pm IST

$₹

Rein Therapeutics Inc Stock Performance

as on September 18, 2025 at 7:37 pm IST

Day's Low
Day's High
$1.13
Day's Price Range
$1.14
$1.16
2.59%
Downside
-1.72%
Upside
52 Week's Low
52 Week's High
$1.04
52-Week Price Range
$3.5
$1.16
10.34%
Downside
201.72%
Upside

Rein Therapeutics Inc share price movements today

Previous Close: $1.15
Open: $1.13
Volume: 28.3K
Day's Low - High: $1.13 - $1.14
52 Week Low - High: $1.04 - $3.5

Rein Therapeutics Inc Historical Returns

1 Month Return: + 1.77 %
3 Month Return: -29.88 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Rein Therapeutics Inc Stock Fundamentals & Key Indicators

Check Rein Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$52.9M

EPS (TTM)

-2.24

Dividend Yield

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

Return On Equity TTM

1033800.00%

Rein Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Rein Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Rein Therapeutics Inc	NA	$52.9M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	241.54%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$99.3B	45.88%	27.56	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$60.9B	5.45%	14.49	31.37%

Rein Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Rein Therapeutics Inc Stock has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:100% versus previous 30 day period

Rein Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	0
Operating Income	0	0	0	0	-6	-42	-5	-6
EBITDA	0	0	0	0	0	0	-5	-6
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	-	-	-	0
Income Before Tax	0	0	0	0	-5	-42	-5	-6
Income Tax Expense	-	-	-	-	-	0	-1	-
Net Income	0	0	0	0	0	-40	-5	-6
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Rein Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	0
Operating Income	0	0	0	0	-65
EBITDA	0	0	0	0	-28
Interest Expense	-	-	-	-	-
Depreciation	0	0	0	0	0
Income Before Tax	0	0	0	0	-64
Income Tax Expense	-	-	-	-	-1
Net Income	0	0	0	0	-62
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Rein Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-1	-1	-7	-7	-8	-5	-40	-5	-6
Operating Cash Flow	-3	-1	-10	-5	-8	-3	-4	-6	-6
Investing Cash Flow	8	0	0	-	-	-	-	-	-
Financing Cash Flow	-	-	15	-	18	0	0	0	4
Change in Cash	5	-1	5	-5	9	-4	-4	-5	-1

Rein Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-18	-22	-31	-29	-21	-26	-27	-15	-62
Operating Cash Flow	-15	-20	-27	-26	-20	-23	-24	-19	-22
Investing Cash Flow	0	-38	24	-2	6	-35	26	16	-
Financing Cash Flow	31	50	2	23	15	55	-	15	17
Change in Cash	16	-8	0	-5	1	-4	1	12	-4

Insights on Rein Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, RNTX stock has moved up by 6.5%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 190.2%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 125.0%

About Rein Therapeutics Inc

Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.

Organisation	Rein Therapeutics Inc
Headquarters	12407 N. Mopac Expy., Austin, TX, United States, 78758
CEO	Dr. James Brian Windsor Ph.D.
E-voting on shares	Click here to vote

Key Management of Rein Therapeutics Inc

Name	Title
Dr. James Brian Windsor Ph.D.	CEO, President & Director
Dr. Cory M. Hogaboam Ph.D.	Chief Scientific Officer
Ms. Jennifer Faigle	Counsel
Mr. Ron Chen	VP of Finance and Corporate Controller

FAQs

What is Rein Therapeutics Inc share price today?

Rein Therapeutics Inc share price today is $1.16 as on September 18, 2025 at 7:37 pm IST. Rein Therapeutics Inc share today touched a day high of $1.14 and a low of $1.13.

What is the 52 week high and 52 week low for Rein Therapeutics Inc share?

Rein Therapeutics Inc share touched a 52 week high of $3.5 on January 29, 2025 and a 52 week low of $1.04 on August 4, 2025. Rein Therapeutics Inc stock price today i.e. September 18, 2025 at 7:37 pm IST is trending at $1.16,which is 66.86% down from its 52 week high and 11.54% up from its 52 week low.

What is Rein Therapeutics Inc's market capitalisation today?

Rein Therapeutics Inc market capitalisation is $0.00T as on September 18, 2025 at 7:37 pm IST.

How to invest in Rein Therapeutics Inc Stock (RNTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Rein Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Rein Therapeutics Inc Shares that will get you 1.2931 shares as per Rein Therapeutics Inc share price of $1.16 per share as on September 18, 2025 at 7:37 pm IST.

What is the minimum amount required to buy Rein Therapeutics Inc Stock (RNTX) from India?

Indian investors can start investing in Rein Therapeutics Inc (RNTX) shares with as little as ₹88.114 or $1 (as of September 18, 2025 at 7:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Rein Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 7:37 pm IST). Based on Rein Therapeutics Inc share’s latest price of $1.16 as on September 18, 2025 at 7:37 pm IST, you will get 8.6207 shares of Rein Therapeutics Inc. Learn more about fractional shares .